Pembrolizumab + nesuparib for endometrial neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 16 Jul 2024: Trial registered, NCT06502743
  2. 12 Sep 2024: Trial started, NCT06502743

The trials

NCT06502743: First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer

State
Under way
Phase
Phase 2
People
92 planned
Started
12 Sep 2024
Primary completion
27 Dec 2027
Arms
Part B - Pembrolizumab and nesuparib combination therapy, Part A - Safety Run-in Phase
Results
None posted
  1. 16 Jul 2024: Trial registered
  2. 12 Sep 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.